MedTrace Logo

Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis

NCT06113991 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-11-02

No results posted yet for this study

Summary

Inhalation of beryllium can induce specific sensitization and diffuse pulmonary granulomatosis called chronic beryllium disease (CBD). The clinical, radiographic, and anatomopathological features of CBD are very similar to those of sarcoidosis, another granulomatosis, making its diagnosis difficult. In addition, the progression of CBD is poorly understood. The investigators hypothesis is that there are specific clinical, biological, anatomopathological, and radiological presentation specificities of CBD, as well as a worse prognosis compared to pulmonary sarcoidosis.

Conditions

  • Pulmonary Sarcoidosis
  • Chronic Beryllium Disease

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-14
Primary Completion
2023-06-14
Completion
2023-12-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06113991 on ClinicalTrials.gov